RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Clinical trials for RELAPSED/REFRACTORY B-CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug AC676 tested in blood cancer patients who have run out of options
Disease control Recruiting nowThis early-stage study tests a new drug called AC676 in about 60 adults with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose and check fo…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Accutar Biotechnology Inc • Aim: Disease control
Last updated May 26, 2026 04:52 UTC
-
New hope for hard-to-treat blood cancers? early trial begins.
Disease control Recruiting nowThis early-phase study tests a new drug, UBX-303061, in people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior treatments. The main goals are to check safety and find the right dose. About 94 adults will take part in this first …
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Ubix Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:49 UTC
-
New injection targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early study tests an injection called IASO208 in 12 adults with relapsed or refractory B-cell blood cancers (like certain lymphomas). The main goal is to check safety and find the right dose, not to cure the disease. Participants must be between 18 and 75 years old and have …
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
New injection targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ZZSW-01 in 6 adults with B-cell blood cancers that have returned or not responded to prior treatments. The main goal is to check safety and side effects, including immune reactions. Researchers will also look for early signs that the…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 26, 2026 04:31 UTC
-
New CAR-T therapy targets tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called BAFFR CAR-T for people with B-cell blood cancers that have returned or not responded to standard therapy. About 28 to 30 adults aged 18 to 85 will receive this therapy to see if it is safe and helps them live longer. The approach uses the p…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New dual-target CAR-T therapy enters human testing for hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new type of CAR-T therapy that targets two proteins (CD19 and CD20) on cancer cells. It is designed for adults with B-cell blood cancers that have relapsed or not responded to standard treatments. The main goals are to check safety, find the right d…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 22, 2026 13:54 UTC